217 related articles for article (PubMed ID: 29549175)
1. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Nahas MR; Soiffer RJ; Kim HT; Alyea EP; Arnason J; Joyce R; Antin JH; Ho VT; Stroopinsky D; Li S; Levine JD; McMasters M; Jain S; Hamdan A; Tzachanis D; Bryant MP; Logan EK; Bazemore J; Stewart J; Joyce A; Stephenson S; Washington A; Cole L; Pyzer A; Leaf RK; Avigan DE; Rosenblatt J
Blood; 2018 Jun; 131(25):2836-2845. PubMed ID: 29549175
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Koshy AG; Kim HT; Liegel J; Arnason J; Ho VT; Antin JH; Joyce R; Cutler C; Gooptu M; Nikiforow S; Logan EK; Elavalakanar P; Narcis M; Stroopinsky D; Avigan ZM; Boussi L; Stephenson S; El Banna H; Bindal P; Cheloni G; Avigan DE; Soiffer RJ; Rosenblatt J
Blood; 2023 Jun; 141(24):2932-2943. PubMed ID: 36862975
[TBL] [Abstract][Full Text] [Related]
3. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis.
Wertheimer T; Dohse M; Afram G; Weber D; Heidenreich M; Holler B; Kattner AS; Neubauer A; Mielke S; Ljungman P; Holler E; Herr W; Edinger M; Martínez AP; Fante M; Wolff D
Ann Hematol; 2021 Mar; 100(3):779-787. PubMed ID: 33515310
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
DeFilipp Z; Li S; Kempner ME; Brown J; Del Rio C; Valles B; Hunnewell C; Saylor M; Vanderklish J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1836-1840. PubMed ID: 29758393
[TBL] [Abstract][Full Text] [Related]
5. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.
Koura DT; Horan JT; Langston AA; Qayed M; Mehta A; Khoury HJ; Harvey RD; Suessmuth Y; Couture C; Carr J; Grizzle A; Johnson HR; Cheeseman JA; Conger JA; Robertson J; Stempora L; Johnson BE; Garrett A; Kirk AD; Larsen CP; Waller EK; Kean LS
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1638-49. PubMed ID: 24047754
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
[TBL] [Abstract][Full Text] [Related]
7. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
9. The effect of budesonide mouthwash on oral chronic graft versus host disease.
Sari I; Altuntas F; Kocyigit I; Sisman Y; Eser B; Unal A; Fen T; Ferahbas A; Ozturk A; Unal A; Cetin M
Am J Hematol; 2007 May; 82(5):349-56. PubMed ID: 17109390
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
[TBL] [Abstract][Full Text] [Related]
12. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
13. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
Akpek G; Lee SM; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
[TBL] [Abstract][Full Text] [Related]
14. A Novel JAK1 Inhibitor SHR0302 Combined With Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease: A Phase I Clinical Trial.
He Q; Sun X; Niu J; Yang J; Wang Y; Huang C; Zhou K; Tong Y; Cai Y; Dong B; Wan L; Song X; Qiu H
Cell Transplant; 2024; 33():9636897241254678. PubMed ID: 38798038
[TBL] [Abstract][Full Text] [Related]
15. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
Yamashita K; Horwitz ME; Kwatemaa A; Nomicos E; Castro K; Sokolic R; Foster SF; Garofalo M; Choi U; Ryherd M; Brown MR; Leitman SF; Wayne AS; Fowler DH; Bishop MR; Childs RW; Barrett AJ; Pavletic SZ; Malech HL
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):22-30. PubMed ID: 16399598
[TBL] [Abstract][Full Text] [Related]
16. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
[TBL] [Abstract][Full Text] [Related]
17. T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation.
Jaiswal SR; Zaman S; Chakrabarti A; Sehrawat A; Bansal S; Gupta M; Chakrabarti S
Transpl Immunol; 2016 Nov; 39():46-51. PubMed ID: 27577170
[TBL] [Abstract][Full Text] [Related]
18. A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease.
Zallio F; Mazzucco L; Monaco F; Astori MR; Passera R; Drago G; Tamiazzo S; Rapetti M; Dolcino D; Guaschino R; Pini M; Ladetto M
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1664-1670. PubMed ID: 27269196
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WJ; Weisdorf DF
Biol Blood Marrow Transplant; 2001; 7(5):265-73. PubMed ID: 11400948
[TBL] [Abstract][Full Text] [Related]
20. Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity.
Hillhouse EE; Thiant S; Moutuou MM; Lombard-Vadnais F; Parat R; Delisle JS; Ahmad I; Roy DC; Guimond M; Roy J; Lesage S
Biol Blood Marrow Transplant; 2019 Jan; 25(1):19-25. PubMed ID: 30244108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
